7 results about "Alkalinizing agent" patented technology

The application belongs to the technical field of starch chemical modification, and particularly relates to a preparation method of acetylated distarch phosphate. The method comprises the following steps: mixing starch with a deep eutectic solvent composed of choline chloride, glycerol and a small amount of water, adding a phosphate crosslinking agent and a delayed-release alkalizing agent for crosslinking reaction after pH adjustment, performing acetylation reaction by adding acetic anhydride or vinyl acetate after cleaning by alcohol solvent replacement, and finally obtaining the product through neutralization, washing, dehydration and drying. The process utilizes the deep eutectic solvent to control water activity and particle structure, and combines the slow-release alkali source to maintain a stable reaction environment, so that the crosslinking and acetylation are uniformly carried out, and the side reactions and residual salt load are effectively reduced. The obtained acetylated distarch phosphate has stable substitution degree, uniform particle structure and excellent performance in freeze-thaw stability, and is suitable for multiple fields such as papermaking, textile and oil field additives.

A hydraulic binder including (in % by dry weight); A. at least 50 of at least one ground and granulated blast-furnace slag; B. more than 5 of at least one calcium aluminate cement and / or of at least one calcium sulfoaluminate cement; C. more than 5 of at least one source of sulfate ions; D. between 1 and 5 of Ca(OH)2 and / or Portland cement; E. between 0.01 and 1 of at least one alkali metal carbonate; F. and at least one alkalifying reagent consisting of at least one alkali metal carbonate and / or bicarbonate, different from E; under the following conditions: (i) amount of C allows sulfate ions of C to react with B and A; (ii) the amount of F sufficiently causes a reaction with D in water resulting in a wet formulation with a pH not less than 12, for a water-to-mortar mixing rate between 10 and 35% by weight.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The application provides a nano cerium dioxide-based fuel additive and a preparation method and application thereof. The preparation method of the nano cerium dioxide-based fuel additive comprises the following steps: mixing a ligand, a dispersing agent, a dissolving oil and an oil phase auxiliary agent to obtain an oil phase; mixing cerium halide, an aqueous phase solvent, an oxidizing agent and an alkalizing agent to obtain an aqueous phase; and reacting the oil phase and the aqueous phase by using a supergravity reaction method to obtain the nano cerium dioxide-based fuel additive. The nano cerium dioxide-based fuel additive can be stably dispersed in fuel.

This invention relates to the field of biomedical technology, and more particularly to a fenelazol microsphere, its preparation method, and capsules. This invention optimizes the formulation of the original fenelazol tablets, using blank pellet cores as a carrier, sodium carbonate as an alkalizing agent, and sulfobutyl-β-cyclodextrin as an excipient to prepare fenelazol microsphere capsules. Experiments show that these microspheres have excellent solubility in gastric acid, are pH-independent, and exhibit high long-term storage stability. This invention simplifies the production process, has good process stability, low production costs, and is suitable for large-scale production.

The application discloses a compound tablet for treating hypertension, which comprises telmisartan, benzenesulfonic acid amlodipine, an alkalizing agent, a binder, a filling agent, a lubricant and a flow aid, and is characterized in that: the benzenesulfonic acid amlodipine is externally attached with a coating film; the coating material of the coating film is a gastric soluble coating material stable under an alkaline condition; and the weight ratio of the coating material to the benzenesulfonic acid amlodipine is (1-2.5): 1. The coating material is one or more of hydroxypropyl methyl cellulose, Eudragit E series and hydroxypropyl cellulose. The application provides a telmisartan amlodipine tablet with high stability and outstanding dissolution performance.

A multi-component packaging unit (kit-of-parts) for the reductive decolorization of dyed keratinous fibers, which is packaged separately, comprises: a container (A) containing a cosmetic agent (a) and a container (B) containing a cosmetic agent (b), wherein the agent (a) in container (A)(a1) comprises one or more sulfinic acid derivatives from the group consisting of: (H2N)(NH)C(SO2H) formamidine sulfinic acid, HN(CH2SO2Na)2, disodium [(sulfinatomethyl)amino]methanesulfinate, HN(CH2SO2K)2, dipotassium [(sulfinatomethyl)amino]methanesulfinate, HN(CH2SO2H)2, [(sulfinomethyl)amino]methanesulfinic acid, N(CH2SO2Na)3, trisodium [bis(sulfinatomethyl)amino]methanesulfinate- N(CH2SO2K)3, tripotassium [bis(sulfinatomethyl)amino]methanesulfinate- N(CH2SO2H)3, [bis(sulfinomethyl)amino]methanesulfinic acid- H2NCH(CH3)SO2Na, sodium 1-aminoethane-1-sulfinate- H2NCH(CH3)SO2K, potassium 1-aminoethane-1-sulfinate- H2NCH(CH3)SO2H, 1-aminoethane-1-sulfinic acid,- HN(CH(CH3)SO2Na)2,Disodium 1-[(1-sulfinatoethyl)amino]ethane-1-sulfinate- HN(CH(CH3)SO2K)2, Dipotassium 1-[(1-sulfinatoethyl)amino]ethane-1-sulfinate- HN(CH(CH3)SO2H)2, 1-[(1-sulfinoethyl)amino]ethane-1-sulfinic acid- N(CH(CH3)SO2Na)3, Trisodium 1-[bis(1-sulfinatoethyl)amino]ethane-1-sulfinate- N(CH(CH3)SO2K)3, Tripotassium 1-[bis(1-sulfinatoethyl)amino]ethane-1-sulfinate and / or- N(CH(CH3)SO2H)3, 1-[bis(1-sulfinoethyl)amino]ethane-1-sulfinic acid contains,(a2) one or more fatty components from the group of C12-C30 fatty alcohols, C12-C30 fatty acid triglycerides, C12-C30 fatty acid monoglycerides, C12-C30 fatty acid diglycerides, C12-C30 fatty acid esters, hydrocarbons and / or silicone oils,(a3) has a water content of not more than 10.0% by weight - based on the total weight of the product (a),- the product (b) in container (B)(b1) has a water content of at least 30.0% by weight - based on the total weight of the product (b),(b2) contains one or more alkalizing agents from the group consisting of ammonia, alkanolamines and / or basic amino acids, and (b3) has a pH of 7.5 to 12.5.